Executive Summary
Complete revascularization after TAVI offers no survival advantage over an incomplete strategy in elderly high-risk patients, per the REVIVAL registry (N=447, 4-year MACE 34.7% vs 35.0%, HR 1.01) — which loosens the case for chasing every residual lesion in post-TAVI PCI. A separate meta-analysis of 96,430 bicuspid AS patients showed TAVR matches SAVR on 30-day mortality and stroke while doubling pacemaker risk — a signal that reinforces, not resolves, the ESC 2025 Class IIb reservation on TAVI for BAV. Incidental interstitial lung abnormalities on pre-TAVR CT emerged as an independent 3-year mortality predictor (57.6% vs 36.4%), confirming the pre-procedural scan is under-read.
- REVIVAL registry: complete vs incomplete revascularization after TAVI shows no 4-year MACE difference in 447 patients (Open Heart).
- BAV meta-analysis of 96,430 patients: TAVR trades lower AF and bleeding for higher pacemaker rates vs SAVR, with no mortality difference (Curr Cardiol Rev).
- Incidental ILA on pre-TAVR CT independently predicted 3-year mortality (HR-adjusted across models) in 600 patients (Heart Lung).
- In-hospital gait speed decline post-TAVI nearly doubled mortality risk (HR 1.9-2.1) in 1,082 patients over 3 years (Circ Rep).
- Sheep model shows tricuspid leaflets remodel irreversibly after pressure overload, offering a mechanistic explanation for recurrent FTR post-treatment (bioRxiv preprint).
What to watch: Edwards Q3 earnings on October 29 will be the first read on whether EVOQUE TTVR adoption is tracking to the ESC 2025 Class IIa upgrade for transcatheter tricuspid therapy.
Aortic Valve (TAVR/TAVI)
Aggressive completeness after TAVI does not improve outcomes; reading the whole CT does. In the REVIVAL registry, 447 patients undergoing PCI after TAVI (2008–2023) showed identical 4-year MACE whether operators pursued complete (70.5%) or incomplete (29.5%) revascularization (HR 1.01, p=0.97). Registry, non-randomized, elderly cohort — but the signal is consistent with the broader post-TAVI PCI literature: residual ischemia is not the dominant driver of late events in this population. ACC/AHA 2020 and ESC 2025 both leave post-TAVI revascularization strategy to Heart Team judgment; this data supports selective, symptom- and physiology-guided PCI over systematic completion.
[NOTABLE] Incidental ILA on pre-TAVR CT was found in 20.8% of ~600 patients and independently predicted 3-year mortality (57.6% vs 36.4%). Emphysema, present in 23.7%, did not. This reframes the pre-procedural CT as a prognostic tool, not just an anatomical planning instrument. A separate 1,082-patient TAVI cohort found in-hospital gait speed decline doubled post-discharge mortality risk (HR 1.9–2.1), regardless of baseline gait. Both findings sharpen the frailty and comorbidity assessment that current guidelines already emphasize but underspecify.
On mechanisms, an Atherosclerosis review catalogs the pharmacological pipeline for AS — Lp(a) antisense oligonucleotides leading, with PCSK9 inhibitors, colchicine, and ataciguat behind. No positive trial yet. A disease-modifying agent would upend the entire intervention-timing debate.
Mitral Valve
Prolapse width predicts TEER durability at 3 years, and the cutoff is 16 mm. In a prospective 27-center Chinese cohort (N=78) of degenerative MR patients undergoing TEER, MR ≤1+ was sustained in 62.8% at 3 years — but only when pre-procedural prolapse/flail width was <16 mm (AUC 0.71, OR 0.79 per mm, p=0.013). Small sample, single-arm, imaging substudy — but the anatomical threshold is actionable. Both ACC/AHA 2020 and ESC 2025 keep surgical MV repair as the standard for symptomatic severe primary MR when a durable result is expected, with TEER reserved for high surgical risk (Class IIa in both). Prolapse width ≥16 mm should push the Heart Team toward surgery, not TEER, when operative risk permits — consistent with the ESC 2025 expansion of Class I early repair criteria in asymptomatic patients meeting risk-factor thresholds.
No surgical MR comparator landed today. The JTCVS Techniques note on SAVR after TAVR — an orthopedic device adapted for cardiac use — is a reminder that TAV explant carries 12–17% mortality and drives lifetime-management planning at the index procedure.
Tricuspid Valve
The tricuspid leaflet doesn't forgive. A bioRxiv preprint from a large-animal (sheep) model shows that after 8 weeks of pulmonary artery banding followed by 8 weeks of unbanding, tricuspid leaflets retain persistent ECM changes, altered PRG4/PDE3A/CXCL8/HLA transcription, and do not revert to normal architecture. RV tissue shows a parallel non-reversing remodeling trajectory. Preclinical, small N — but the mechanism matters: FTR treatment doesn't just need to relieve hemodynamic load; it may need to intervene before leaflet remodeling becomes fixed. That aligns with the ESC 2025 Class IIa upgrade for transcatheter TV treatment in symptomatic severe TR without severe RV dysfunction, and with both guidelines' emphasis on the too-late-referral problem. Waiting for RV failure means waiting past the point where the valve itself can recover. ESC 2025's Class IIa recommendation is grounded in TRILUMINATE Pivotal, Tri.Fr, and TRISCEND II; ACC/AHA 2020 remains silent on transcatheter TR therapy entirely.
Surgical vs. Transcatheter Comparisons
The bicuspid AS meta-analysis (N=96,430) is the day's headline comparison. TAVR delivered lower rates of new AF, respiratory complications, and transfusion, but higher pacemaker rates. No difference in short-term mortality, stroke, or AKI. Seven observational studies, no RCTs — because BAV patients were excluded from every landmark TAVR trial. This is exactly the evidence gap that keeps both ACC/AHA 2020 and ESC 2025 at Class IIb for TAVI in BAV. The meta-analysis quantifies why the guidelines are cautious; it does not change the calculus. NOTION-2's numerically worse TAVI signal in 100 BAV patients (HR 3.8, p=0.07) still hangs over the field.
The Konno AVR series (N=19) demonstrates that surgical annular enlargement can upsize a small annulus by 2–3 prosthesis sizes and optimize root anatomy for future ViV-TAVR — no in-hospital mortality, but new conduction delay (QRS 90→114 ms) and RV functional decline flag longer-term concerns. This is precisely the lifetime-management planning ESC 2025 now demands at the index procedure: careful CT-based anatomical analysis when life expectancy exceeds assumed valve durability.
Preprint Highlights
The Timek group's tricuspid remodeling study (covered in the Tricuspid section) is the standout — a mechanistic case for earlier FTR intervention. A second bioRxiv preprint characterizes a de novo desmin p.R406W mutation causing severe ventricular arrhythmias and SCD in a 9-year-old, using hiPSC-CMs and a knock-in mouse. Not directly valve-related, but the platform is increasingly relevant for characterizing genetic modifiers of structural heart disease phenotypes.
Device & Technology
Edwards has reportedly solved a leading cause of tissue valve failure, per Medical Design & Outsourcing. Details are thin in the source. If durability improvements survive independent scrutiny, this is the most consequential structural valve engineering story of the year — SVD at 10 years is the single largest limiter on TAVI expansion into younger patients. The claim is company-sourced. Wait for peer-reviewed durability data before drawing conclusions.
A separate SCCT 2026 keynote from Ed Nicol outlined non-contrast cardiac CT with AI-driven fat attenuation index as a future preventive screening tool. Interesting, distant.
Regulatory & Policy
No new FDA or CE mark actions today.
Financial Analysis
Edwards was up 1.77% to $93.66 on the reported durability-engineering news, extending a 22.5% six-month run and now trading near the $96.29 52-week high. Seeking Alpha's "cheap against itself, expensive against everything else" framing captures the tension: EW's forward P/E of 27.75 is rich against the broader medtech comp set but defensible given TTVR (EVOQUE) tailwinds, the SAPIEN franchise's position in the ESC 2025 age ≥70 preferred zone, and — if it survives peer review — a durability story that addresses the field's single biggest obstacle to TAVI in younger patients. Insider selling (a 619-share Form 144) is trivial and routine. Boston Scientific's 6-month drawdown (-31%) reflects broader medtech pressure and PFA cycle skepticism, not structural heart-specific concerns.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close: $93.66 (+1.77%); 6-month: +22.53%
- Market cap: $54.0B | Trailing P/E: 54.77 | Forward P/E: 27.75 | Beta: 0.85
- 52-week range: $72.30–$96.29
- Analyst target: $100.96 (26 analysts, buy consensus)
- Next earnings: Oct 29, 2026 (EPS est: $0.74; Rev est: $1.68B)
Trading near 52-week highs on the tissue-durability engineering headline and continued EVOQUE momentum. The stock has decoupled from the broader medtech complex over the last six months.
Medtronic (MDT)
- Close: $90.68 (+1.42%); 6-month: -8.56%
- Market cap: $116.1B | Trailing P/E: 23.99 | Forward P/E: 14.14 | Beta: 0.57
- 52-week range: $73.31–$106.33
- Analyst target: $98.44 (25 analysts, buy consensus)
- Next earnings: Sep 1, 2026 (EPS est: $1.39; Rev est: $9.55B)
Evolut FX+ competes in the ESC 2025 tricuspid-AV/age ≥70 preferred zone, but MDT's diversified base has capped upside relative to pure-play EW.
Abbott (ABT)
- Close: $109.72 (+1.01%); 6-month: -0.25%
- Market cap: $189.9B | Trailing P/E: 35.51 | Forward P/E: 18.10 | Beta: 0.58
- 52-week range: $81.97–$137.49
- Analyst target: $118.42 (24 analysts, buy consensus)
- Next earnings: Oct 14, 2026 (EPS est: $1.42; Rev est: $12.99B)
MitraClip and TriClip position ABT directly against the ESC 2025 Class I TEER upgrade for ventricular SMR and the Class IIa transcatheter TR indication. Structural heart is a growing but still minority contributor to the overall revenue base.
Boston Scientific (BSX)
- Close: $51.19 (+1.45%); 6-month: -30.94%
- Market cap: $74.2B | Trailing P/E: 20.72 | Forward P/E: 14.89 | Beta: 0.57
- 52-week range: $42.20–$109.50
- Analyst target: $62.69 (29 analysts, buy consensus)
- Next earnings: Oct 28, 2026 (EPS est: $0.81; Rev est: $5.26B)
The 31% six-month drawdown reflects broader EP/PFA cycle concerns rather than structural heart specifically. Acurate neo2 remains in the SAVR-preferred sub-70 zone per ESC 2025.
Anteris Technologies (AVR.AX)
- Close: A$12.85 (+2.39%); 6-month: +60.63%
- Market cap: A$1.3B | Forward P/E: -5.89 | Beta: 0.73
- 52-week range: A$5.20–A$15.47
- Analyst target: A$13.00 (1 analyst)
DurAVR THV early-feasibility momentum has driven the run. Thin analyst coverage; execution risk remains the story.
Market outlook: The day's news — durability engineering at Edwards, the tricuspid leaflet remodeling preprint arguing for earlier intervention, and reinforcement that BAV remains a TAVR gray zone — all favor the incumbent balloon-expandable franchise. Edwards' relative outperformance vs the medtech complex over six months is underwritten by both the ESC 2025 tricuspid expansion and, potentially, a durability answer that would extend TAVI's runway into younger patients.
Clinical Trial Updates
Mitral Repair
- NCT07757607 — MRace for FMR with complex M-TEER anatomies (France cohort). Status: Not yet recruiting. Phase: NA. Enrollment: 20. Sponsor: Polares Medical SA. Link
- NCT07757698 — MRace for FMR with complex M-TEER anatomies (Australia cohort). Status: Not yet recruiting. Phase: NA. Enrollment: 15. Sponsor: Polares Medical SA. Link
- NCT07757776 — MRace for FMR with complex M-TEER anatomies (Germany cohort). Status: Not yet recruiting. Phase: NA. Enrollment: 20. Sponsor: Polares Medical SA. Link
Polares Medical is standing up a three-country registry for its MRace device targeting FMR patients whose anatomy defeats conventional MitraClip/PASCAL leaflet grasping. Small (N=55 total across sites) and single-arm — this is evidence-base building for a niche within a niche. The ESC 2025 Class I upgrade for TEER in ventricular SMR expands the ceiling: if MRace can address the anatomic exclusions that keep patients out of COAPT-like eligibility, the addressable population grows with it.
Forward look: The next inflection is durability data. If Edwards' engineering claim survives peer review, and if independent long-term TAVI cohorts continue to match SAVR SVD rates through 10 years, the ESC 2025 age-70 threshold will look conservative within 24 months. Until then, the sub-70 SAVR-preferred zone holds — reinforced today by the BAV meta-analysis, the Konno series, and the tricuspid leaflet-remodeling reminder that late is not the same as never.